BioNTech's HER2-Low Breast Cancer Drug Hits Its Trial Goal, But The Companies Call The Likely Benefit 'Limited'

A 541-patient late-stage trial showed a modest progression-free survival gain, with more lung disease than in earlier studies of the drug.

Share
BioNTech's HER2-Low Breast Cancer Drug Hits Its Trial Goal, But The Companies Call The Likely Benefit 'Limited'

BioNTech and its partner DualityBio said their late-stage breast cancer trial met its main goal, but the gain was modest and the companies themselves expect the benefit to patients to be limited. The release, dated Monday, also reported a higher rate of interstitial lung disease than in earlier trials of the drug, trastuzumab pamirtecan.

A win on paper, a modest one in practice

The DYNASTY-Breast02 trial showed a statistically significant but modest improvement in progression-free survival, the time before the cancer worsens. The comparison was against chemotherapy chosen by the investigator, in patients with HR+/HER2-low metastatic breast cancer whose disease had progressed on endocrine therapy and who had not yet had chemotherapy.

The trial randomized 541 patients with HER2-low expression 1:1 to trastuzumab pamirtecan or a single chemotherapy drug: capecitabine, paclitaxel or nab-paclitaxel. Overall survival, a secondary measure, was not mature at this interim analysis.

The companies were blunt about what it adds up to. The data so far "suggest that the potential benefit to patients would be limited" in the current treatment landscape for this cancer, they said.

More lung disease than before

Interstitial lung disease, a lung condition, appeared at a higher rate than in prior trastuzumab pamirtecan trials. Most cases were Grade 1 and 2, while severe and fatal events (Grade 3-5) occurred in a small proportion of patients.

Otherwise, the companies said, the safety profile matched earlier trials and no new safety signals appeared.

The drug and its developers

BioNTech, the Mainz-based immunotherapy company behind the COVID-19 vaccine Comirnaty, focuses mainly on oncology. Trastuzumab pamirtecan is a third-generation antibody-drug conjugate targeting HER2, built from DualityBio's platform and developed jointly by the two companies.

The drug is also in a Phase 3 trial in HER2-expressing recurrent endometrial cancer and a Phase 1/2 trial in advanced or metastatic solid tumors. BioNTech's market value was $22.1 billion in Monday's pre-market reporting.

The companies said they will discuss the data and determine next steps.

The two companies' next step is a discussion of the data; their release sets no date for it.

Sources

More on BioNTech

All BioNTech (BNTX) coverage →